MARKET

SLNO

SLNO

SOLENO THERAPEUT
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.650
+0.240
+9.96%
Pre Market: 2.650 0 0.00% 08:09 03/02 EST
OPEN
2.460
PREV CLOSE
2.410
HIGH
2.660
LOW
2.440
VOLUME
3
TURNOVER
--
52 WEEK HIGH
4.390
52 WEEK LOW
1.300
MARKET CAP
210.98M
P/E (TTM)
-3.5202
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Prader-Willi syndrome - Pipeline Insight, 2020
Feb 26, 2021 (Heraldkeepers) -- DelveInsight's, "Prader-Willi syndrome - Pipeline Insight, 2020," report provides comprehensive insights about 20+ companies...
Heraldkeepers · 4d ago
Soleno Therapeutics, Vanderbilt University In Research Pact For K(ATP) Channel Activators
Benzinga · 6d ago
BRIEF-Soleno Therapeutics Collaborates With Vanderbilt University To Discover, Develop Next Generation Channel Activators For Treatment Of Rare Diseases
reuters.com · 02/23 14:03
Soleno Therapeutics inks research deal with Vanderbilt University
Soleno Therapeutics (SLNO) has signed a collaboration agreement with Vanderbilt University to discover and develop novel KATP channel activators with the potential to treat rare diseases.ATP-dependent potassium (or KATP) channels are
Seekingalpha · 02/23 13:21
Soleno Therapeutics Announces Collaboration With Vanderbilt University To Discover And Develop KATP Channel Activators For Treatment Of Rare Diseases; Financial Details Not Disclosed
REDWOOD CITY, Calif., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. ("Soleno") (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare
Benzinga · 02/23 13:06
Soleno Therapeutics Announces Collaboration with Vanderbilt University to Discover and Develop Next Generation K(ATP) Channel Activators for the Treatment of Rare Diseases
Soleno Therapeutics, Inc. ("Soleno") (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it has signed a collaboration agreement with Vanderbilt University. This ...
GlobeNewswire · 02/23 13:00
Soleno Therapeutics, Vanderbilt University Sign Deal to Develop Potential Rare Disease Treatments
MT Newswires · 02/23 12:04
8-K: SOLENO THERAPEUTICS INC
Edgar Online - (EDK = 8-Ks/S1/S-4) · 02/05 21:40
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of SLNO. Analyze the recent business situations of SOLENO THERAPEUT through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average SLNO stock price target is 8.67 with a high estimate of 9.00 and a low estimate of 8.00.
EPS
Institutional Holdings
Institutions: 98
Institutional Holdings: 44.94M
% Owned: 56.45%
Shares Outstanding: 79.62M
TypeInstitutionsShares
Increased
22
4.69M
New
19
-2.75M
Decreased
20
1.34M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.13%
Pharmaceuticals & Medical Research
+1.38%
Key Executives
Chairman/Independent Director
Ernest Mario
Chairman/Independent Director
Ernie Mario
President/Chief Executive Officer/Director
Anish Bhatnagar
Chief Financial Officer/Chief Accounting Officer
James Mackaness
Vice President
Patricia Hirano
Vice President
Kristen Yen
Independent Director
William Harris
Independent Director
Gwen Melincoff
Independent Director
Andrew Sinclair
Independent Director
Birgitte Volck
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
About SLNO
Soleno Therapeutics, Inc., formerly Capnia, Inc., is a healthcare company that develops and commercializes neonatology devices and diagnostics. The Company also has a therapeutics platform based on its proprietary technology for precision metering of gas flow. The Company offers products, such as CoSense end-tidal carbon monoxide (ETCO) Monitor, NeoPIP Infant Resuscitator and Accessories, and Serenz Nasal Relief. The Company has developed the CoSense End-Tidal Carbon Monoxide Monitor that measures ETCO for the detection of dangerous hemolysis rates. The Infant Solutions product line, including the NeoPIP Infant Resuscitator Unit and accessories, is designed for controlled and accurate resuscitation of neonates and infants in the clinical environment. Serenz Nasal Relief is a hand-held nasal irrigator that uses carbon dioxide (CO2) gas to wash the nasal passages.

Webull offers kinds of Soleno Therapeutics Inc stock information, including NASDAQ:SLNO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SLNO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading SLNO stock methods without spending real money on the virtual paper trading platform.